Loading organizations...
§ Private Profile · Oxford, Oxfordshire, United Kingdom
AI medical technology company developing AI imaging biomarkers and decision support software for hospitals, focused on stroke.
Based in Oxford, United Kingdom, Brainomix develops AI-powered imaging biomarkers and decision support software to assist physicians in diagnosing and treating stroke patients. The company's flagship platform analyzes CT brain scans to deliver real-time clinical insights, and the FDA-approved technology is currently deployed in more than 300 hospitals across 20 countries. Operating with an estimated 50 to 99 employees, the medical technology firm has impacted over 1.5 million patients globally while expanding its diagnostic capabilities into lung fibrosis and oncology. Brainomix has raised over €30 million in total venture capital funding across six rounds, backed by prominent institutional investors including Parkwalk, Boehringer Ingelheim Venture Fund, Hostplus, and the University of Oxford Innovation Fund. The enterprise was originally founded in 2010 as a spinout from the University of Oxford by Dr. Michalis Papadakis and Andrew Barker.
Brainomix has raised $70.3M across 8 funding rounds.
Brainomix has raised $70.3M in total across 8 funding rounds.
Brainomix has raised $70.3M across 8 funding rounds. Most recently, it raised $6.5M Series C Extension in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 24, 2026 | $6.5M Series C Plus | Hostplus, Parkwalk Advisors | Sahirzeeshan (Sahir) ALI | Announced |
| Mar 1, 2025 | $18M Series C | Parkwalk Advisors, Oliver Reuss, Hostplus | Boehringer Ingelheim Venture Fund, Lifesci Capital | Announced |
| Dec 1, 2021 | $21M Series B | Parkwalk Advisors, Oliver Reuss | Boehringer Ingelheim Venture Fund, Oxford University, Tencent Holdings | Announced |
| Apr 3, 2018 | $9.8M Venture Round | Parkwalk Advisors | Boehringer Ingelheim, Chimera Partners, Oxford University | Announced |
| Apr 1, 2018 | $10M Series U | — | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | Announced |
| Oct 1, 2016 | $2M Series B | — | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | Announced |
| Aug 10, 2015 | $980K Grant | Innovate UK, Medical Research Council | — | Announced |
| Sep 1, 2014 | $2M Series A | — | Boehringer Ingelheim Venture Fund, Parkwalk Advisors | Announced |
Brainomix has raised $70.3M in total across 8 funding rounds.
Brainomix's investors include Hostplus, Parkwalk Advisors, Sahirzeeshan (Sahir) Ali, Oliver Reuss, Boehringer Ingelheim Venture Fund, LifeSci Capital, Oxford University, Tencent, Boehringer Ingelheim, Chimera Partners, Innovate UK, Medical Research Council.
Brainomix is a medical software company specializing in AI-powered imaging biomarkers for precision medicine, primarily targeting stroke and lung fibrosis. It develops the Brainomix 360 platform, including tools like e-Stroke and e-Lung, which analyze brain and lung scans in real-time to support clinicians in making faster, more accurate treatment decisions—such as identifying stroke patients eligible for mechanical thrombectomy or predicting lung fibrosis progression.[1][2][3][4][6] Serving hospitals, stroke networks, and physicians worldwide, Brainomix addresses critical delays in diagnosis and treatment, where patients lose millions of brain cells per minute during strokes; its FDA-cleared and CE-marked solutions have boosted thrombectomy rates by over 50% in real-world use, benefiting over 1.5 million patients across 300+ hospitals in 20+ countries.[3][5][6][7] Recent momentum includes a £14M ($18M) Series C funding round in 2024 to expand its transformative AI tech, nationwide deployments in Wales and Hungary, and partnerships like with Boehringer Ingelheim.[3][7]
Founded in 2010 as a spin-out from the University of Oxford's Nuffield Department of Clinical Neurosciences, Brainomix emerged from research in AI-driven medical imaging to improve stroke diagnosis.[1][3][4][5][9] Dr. Michalis Papadakis, the CEO and co-founder, leads the company, drawing on Oxford's scientific expertise to pioneer tools like the e-Stroke platform for real-time CT scan analysis of brain damage.[4] Early traction came from award-winning biomarkers that enabled remote access to imaging data, evolving from stroke focus to include lung fibrosis with FDA-cleared e-Lung tech; pivotal moments include NICE endorsement, global expansion to the US and 20+ countries, and clinical studies validating impact, such as tripling functional independence rates at sites like Royal Berkshire Hospital.[3][5][7][8]
Brainomix rides the AI in precision medicine wave, particularly in neuroimaging and chronic disease prediction, amid rising stroke incidence (global leader in thrombectomy AI) and demand for scalable diagnostics post-COVID.[3][7][8] Timing aligns with regulatory progress (FDA/CE clearances) and health system pressures for efficiency, as AI bridges radiologist shortages and enables thrombectomy expansion to late-window patients, influencing ecosystems via nationwide rollouts (e.g., all Welsh/Hungarian stroke centers) and media validation from NHS leaders.[5][7][8] It shapes stroke care by standardizing decisions, boosting outcomes, and extending to lung fibrosis, fostering AI adoption in public health systems and attracting healthtech investors.[3][9]
Brainomix is poised for accelerated US growth post-Series C, with e-Lung partnerships potentially mirroring stroke success in fibrosis markets, while expanding AI biomarkers to other conditions.[3][9] Trends like real-world evidence mandates, AI-healthcare integration, and value-based care will propel it, evolving its influence from stroke pioneer to multi-disease platform leader—ultimately saving more lives through precision decisions, as its Oxford roots continue driving global impact.[1][3][7]